D.R. Horton
DHI
Lennar Corp
LEN
KB Home
KBH
4
Petroleo Brasileiro SA Petrobras
PBR
5
Ecopetrol
EC
US Stock MarketDetailed Quotes
VTYX Ventyx Biosciences
- 1.420
- -0.070-4.70%
Close Mar 10 16:00 ET
- 1.421
- +0.001+0.04%
Post 19:39 ET
101.00MMarket Cap-0.72P/E (TTM)
1.470High1.400Low657.75KVolume1.460Open1.490Pre Close941.88KTurnover1.37%Turnover RatioLossP/E (Static)71.13MShares8.12052wk High0.40P/B67.95MFloat Cap1.37052wk Low--Dividend TTM47.85MShs Float47.251Historical High--Div YieldTTM4.70%Amplitude1.370Historical Low1.431Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
As China's 'two sessions' commence: How will Chinese stocks perform?
🎙️Discussion 1. With the government's emphasis on technological innovation and sustainability, which industry sectors do you believe hold t
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Ventyx Biosciences Stock Forum
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025
Tuesday, 18th February at 8:00 am
Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers
Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958
...
Ventyx Biosciences Announces Presentation of Data From the Phase 2 Trial of Allosteric Tyk2 Inhibitor Vtx958 in Crohn’s Disease at Ecco 2025
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
$Yalla (YALA.US)$ diversity outside Asia/us, expanding reach
$NexGel (NXGL.US)$ specialized medical applications will see higher demand as the saline shortage goes on, and more look to alternatives
$Lumen Technologies (LUMN.US)$ ongoing transitions, personally see an increase in presence (which is impressive, honestly, I'm a nobody in random town), and they are approaching good buy levels
$Rezolute (RZLT.US)$ also approaching oversold
$Ventyx Biosciences (VTYX.US)$ impressiv...
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
Ventyx Biosciences (Nasdaq: VTYX) presented new 52-week results from the Phase 2 trial of VTX002 (tamuzimod) in ulcerative colitis at UEG Week 2024. The late-breaking abstract highlighted high rates of clinical and endoscopic remission among long-term extension (LTE) completers at Week 52. CEO Raju Mohan emphasized the data's reinfo...
📊⚡️📊
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price...
No comment yet